Interleukin-12, an emerging anti-tumour cytokine

In Vivo

Volumn 11, Issue 2, 1997, Pages 125-132

  Hiscox, Steve ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cancer treatment; Cytokine; Interleukin 12; Lymphocyte; Metastasis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; UVOMORULIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; EXPRESSION VECTOR; HOST RESISTANCE; HUMAN; MACROPHAGE; METASTASIS; NATURAL KILLER CELL; NONHUMAN; RETROVIRUS; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR REGRESSION;

EID: 0030968912     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Gately MK, Wilson DE, and Wong HL: Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol 136: 1274-1282, 1986.
2. Wong HL, Wilson DE, Jenson JC, Familletti PC, Stremlo DL, and Gately MK: Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 111: 39-54, 1988.
3. Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, and Chizzonite R: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87: 6808-6812, 1990.
4. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, and Trinchieri G: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170: 827-845, 1989.
5. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM and Familletti PC: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88: 4143-4147, 1991.
6. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, and Hewick RM: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146: 3074-3081, 1991.
7. Podlaski FJ, Nanduri VB, Hulmes JD, Pan YC, Levin W, Danho W, Chizzonite R, Gately MK, and Stern AS: Molecular characterization of interleukin 12. Arch Biochem Biophys 294: 230-237, 1992.
8. Merberg DM, Wolf SF, and Clark SC: Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today 13: 77-88, 1992.
9. Sieburth D, Jabs EW, Warrington JA, Li X, Lasota J, LaForgia S, Kelleher K, Huebner K, Wasmuth JJ, and Wolf SF: Assignment of genes encoding a unique cytokine (IL12) composed of two unrelated subunits to chromosomes 3 and 5. Genomics 14: 59-62, 1992.
10. Gearing DP and Cosman D: Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell 66: 9-10, 1991.
11. Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W, Familletti PC, Gately MK and Gubler U: Cloning and expression of murine IL-12. J Immunol 148: 3433-3440, 1992.
12. Shaw G and Kamen R: A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46: 659-667, 1986.
13. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, and Cerami A: Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 83: 1670-1674, 1986.
14. Wolf SS and Cohen A: Expression of cytokines and their receptors by human thymocytes and thymic stromal cells. Immunology 77: 362-368, 1992.
15. D'Andrea A, Rengaraju M, Valiante NM, Chemini J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolf SF, and Trinchieri G: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 176: 1387-1398, 1992.
16. Muller G, Saloga J, Germann T, Bellinghausen I, Mohamadzadeh M, Knop J, and Enk AH: Identification and induction of human keratinocyte-derived IL-12. J Clin Invest 94: 1799-805, 1994.
17. Jiang WG and Puntis MCA: Monocyte production of interleukin-12 in patients with obstructive jaundice. HPB Surgery 9: 219-221, 1996.
18. Cassatella MA, Meda L, Gasperini S, A DA, Ma X, and Trinchieri G: Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol 25: 1-5, 1995.
19. Smith TJ, Ducharme LA, and Weis JH: Preferential expression of interleukin-12 or interleukin-4 by murine bone marrow mast cells derived in mast cell growth factor or interleukin-3. Eur J Immunol 24: 822-826, 1994.
20. Zhan Y, Kelso A, and Cheers C: Cytokine production in the murine response to brucella infection or immunization with antigenic extracts. Immunology 80: 58-464, 1993.
21. Skeiky YA, Guderian JA, Benson DR, Bacelar O, Carvalho EM, Kubin M, Badaro R, Trinchieri G, and Reed SG: A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 181: 1527-1537, 1995.
22. Gazzinelli RT, Hayashi S, Wysocka M, Carrera L, Kuhn R, Muller W, Roberge F, Trinchieri G, and Sher A: Role of IL-12 in the initiation of cell mediated immunity by Toxoplasma gondii and its regulation by IL-10 and nitric oxide. J Eukaryotic Microbiology 41: 9S, 1994.
23. Sieling PA, Wang XH, Gately MK, Oliveros JL, McHugh T, Barnes PF, Wolf SF, Golkar L, Yamamura M, and Yogi Y: IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J Immunol 153: 3639-3647, 1994.
24. Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately M, and Delespesse G: Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 25: 1125-1128, 1995.
25. Hayes MP, Wang J, and Norcross MA: Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 86: 646-650, 1995.
26. Benjamin D, Sharma V, Kubin M, Klein JL, Sartori A, Holliday J, and Trinchieri G: IL-12 expression in AIDS-related lymphoma B cell lines. J Immunol 156: 1626-1637, 1996.
27. Yawalkar N, Limat A, Brand CU, and Braathen LR: Constitutive expression of both subunits of interleukin-12 in human keratinocytes. J Invest Dermatol 106: 80-83, 1996.
28. Chizzonite R, Truitt T, Desai BB, Nunes P, Podlaski FJ, Stern AS, and Gately MK: IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol. 148: 3117-3124, 1992.
29. Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, Warrier RR, Presky DH, Levine JF, and Gately MK: Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 153: 128-136, 1994.
30. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, and Gately MK: IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 148: 3125-3132, 1992.
31. Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, Warrier RR, Presky DH, Levine JF, and Gately MK: Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 153: 128-36, 1994.
32. Stern AS, Magram J, and Presky DH: Interleukin-12 an integral cytokine in the immune response. Life Sci 58: 639-54, 1996.
33. Naume B, Gately MK, Desai BB, Sundan A, and Espevik T: Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine 5: 38-46, 1993.
34. Pignata C, Prasad KV, Hallek M, Druker B, Rudd CE, Robertson MJ, and Ritz J: Phosphorylation of src family lck tytosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol 165: 211-216, 1995.
35. Bacon CM, McVicar DW, Ortaldo JR, Rees RC, JJ OS, and Johnston JA: Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 181: 399-404, 1995.
36. Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell JE, Jr., and Murphy KM: Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 181: 1755-1762, 1995.
37. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, and Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 136: 2348-2357, 1986.
38. Mosmann TR and Coffman RL: Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 46: 111-47, 1989.
39. Mosmann TR and Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 7: 145-73, 1989.
40. Bottomly K: A functional dichotomy in CD4+ T lymphocytes. Immunol Today 9: 268-274, 1988.
41. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, A OG, and Murphy KM: Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549, 1993.
42. Seder RA, Gazzinelli R, Sher A, and Paul WE: Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 90: 10188-10192, 1993.
43. Wu CY, Demeure C, Kiniwa M, Gately M, and Delespesse G: IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. J Immunol 151: 1938-1949, 1993.
44. Manetti R, Annunziato F, Tomasevic L, Gianno V, Parronchi P, Romagnani S, and Maggi E: Polyinosinic acid: polycytidylic acid promotes T helper type 1-specific immune responses by stimulating macrophage production of interferon-alpha and interleukin-12. Eur J Immunol 25: 2656-2660, 1995.
45. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, and Gately MK: Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177: 1505-1509, 1993.
46. Wang ZE, Zheng S, Corry DB, Dalton DK, Seder RA, Reiner SL, and Locksley RM: Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci USA 91: 12932-12936, 1994.
47. Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, and Schaub RG: Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 177: 1797-1802, 1993.
48. Finkelman FD, Madden KB, Cheever AW, Katona IM, Morris SC, Gately MK, Hubbard BR, Gause WC, and Urban JF, Jr: Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode. J Exp Med 179: 1563-1572, 1994.
49. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, and Romagnani S: Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177: 1199-11204, 1993.
50. Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP, Sampognaro S, Maggi E, Romagnani S, and Trinchieri G: Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 179: 1273-83, 1994.
51. Schmitt E, Hoehn P, Huels C, Goedert S, Palm N, Rude E, and Germann T: T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol 24: 793-8, 1994.
52. Schmitt E, Hoehn P, Germann T, and Rude E: Differential effects of interleukin-12 on the development of naive mouse CD4+ T cells. Eur J Immunol 24: 343-347, 1994.
53. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, and Abbas AK: Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 152: 2172-2179, 1994.
54. Morris SC, Madden KB, Adamovicz JJ, Gause WC, Hubbard BR, Gately MK, and Finkelman FD: Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 152: 1047-1056, 1994.
55. Kiniwa M, Gately M, Gubler U, Chizzonite R, Fargeas C, and Delespesse G: Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clinical Investigation 90: 262-266, 1992.
56. Scott P: IL-12: initiation cytokine for cell-mediated immunity. Science 260: 496-497, 1993.
57. Tripp CS, Wolf SF, and Unanue ER: Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA. 90: 3725-3729, 1993.
58. Tripp CS, Gately MK, Hakimi J, Ling P, and Unanue ER: Neutralization of IL-12 decreases resistance to Listeria in SCID and C.B-17 mice. Reversal by IFN-gamma. J Immunol 152: 1883-1887, 1994.
59. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, and Sher A: Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA. 90: 6115-6119, 1993.
60. Bancroft GJ, Schreiber RD, and Unanue ER: Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the seid mouse. Immunol Rev 124: 5-24, 1991.
61. Tripp CS, Gately MK, Hakimi J, Ling P, and Unanue ER: Neutralization of IL-12 decreases resistance to Listeria in SCID and C.B-17 mice. Reversal by IFN-gamma. J Immunol 152: 1883-1887, 1994.
62. Sieling PA and Modlin RL: Regulation of cytokine patterns in leprosy. Ann NY Acad Sei 730: 42-52, 1994.
63. Sieling PA and Modlin RL: Cytokine patterns at the site of mycobacterial infection. Immunobiology 191: 378-387, 1994.
64. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, and Barnes PF: T cell cytokinc responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 94: 2435-2442, 1994.
65. Zhang M, Gately MK, Wang E, Gong J, Wolf SF, Lu S, Modlin RL, and Barnes PF: Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 93: 1733-1739, 1994.
66. Orange JS, Wolf SF, and Biron CA: Effects of IL-12 on the response and susceptibility to experimental viral infections. J Immunol 152: 1253-1264, 1994.
67. Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, and Biron CA: Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med 181: 901-914, 1995.
68. Gazzinelli RT, Giese NA, and Morse HCr: In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 180: 2199-208, 1994.
69. Chehimi J, Starr SE, Frank I, A DA, Ma X, MacGregor RR, Sennelier J, and Trinchieri G: Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 179: 1361-6, 1994.
70. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, and Shearer GM: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262: 1721-4, 1993.
71. Jacobsen SE, Veiby OP, and Smeland EB: Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med 178: 413-418, 1993.
72. Hirayama F, Katayama N, Neben S, Donaldson D, Nickbarg EB, Clark SC, and Ogawa M: Synergistic interaction between interleukin-12 and steel factor in support of proliferation of murine lymphohematopoietic progenitors in culture. Blood 83: 92-98, 1994.
73. Bellone G and Trinchieri G: Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 153: 930-937, 1994.
74. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, and Sher A: Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA 90: 6115-6119, 1993.
75. Romani L, Mencacci A, Tonnetti L, Spaccapelo R, Cenci E, Puccetti P, Wolf SF, and Bistoni F: IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol 153: 5167-5175, 1994.
76. Wynn TA, Eltoum I, Oswald IP, Cheever AW, and Sher A: Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med 179: 1551-1561, 1994.
77. Oswald IP, Caspar P, Jankovic D, Wynn TA, Pearce EJ, and Sher A: IL-12 inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni. J Immunol 153: 1707-1713, 1994.
78. Wynn TA, Eltoum I, Oswald IP, Cheever AW, and Sher A: Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med 179: 1551-1561, 1994.
79. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, and Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993.
80. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, and Storkus WJ: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1706, 1994.
81. Verbik DJ, Stinson WW, Brunda MJ, Kessinger A, and Joshi SS: In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin Exp Metastasis 14: 219-29, 1996.
82. Fallarino F, Uyttenhove C, Boon T, and Gajewski TF: Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol 156: 1095-100, 1996.
83. Noguchi Y, Jungbluth A, Richards EC and Old LJ: Effect of interleukin-12 on tumour inductionby 3-methylchloranthrene. Proc Natl Acad Sci USA 93: 11798-11801, 1996.
84. Tahara H and Lotze MT: Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 2: 96-106, 1995.
85. Kubin M, Kamoun M, and Trinchieri G: Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 180: 211-22, 1994.
86. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SLC and Chen SH: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 93: 11302-11306, 1996.
87. Zitvogel L, Tahara H, Cai Q, Storkus WJ, Muller G, Wolf SF, Gately M, Robbins PD, and Lotze MT: Construction and characterization of retroviral vectors expressing biologically active human intetleukin-12. Human Gene Therapy 5: 1493-1506, 1994.
88. Tahara H, Zitvogel L, Storkus WJ, Zeh HJr, McKinney TG, Schreiber RD, Gubler U, Robbins PD, and Lotze MT: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154: 6466-6474, 1995.
89. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, and Lotze MT: Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155: 1393-1403, 1995.
90. Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K, and Yang NS: Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93: 6291-6296, 1996.
91. Jiang WG, Puntis MCA and Hallett MB: The molecular and cellular mechanisms of cancer invasion and metastasis, implications for treatment. Br J Surg 81: 1576-1590, 1994
92. Hiscox S, Hallett MB, Puntis MC, and Jiang WG: Inhibition of cancer cell motility and invasion by interleukin-12. Clin Exp Metastasis 13: 396-404, 1995.
93. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, and Gately MK: Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother 17: 71-77, 1995.
94. Jiang WG: E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surg 83: 437-446, 1996.
95. Doki Y, Shiozaki H, Tahara H, Inoue M, Oda H, Iihara K, Kadowaki T, Takeichi M, and Mori T: Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 53: 3421-3426, 1993.
96. Voest EE, Kenyon BB, Oreilly MS, Truitt G, Damato RJ and Folkman J: Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 87: 581-586, 1995.
97. Lotze MT: T-cell growth factors and the treatment of patients with cancer. Clin Immunol Immunopathol 180: 547-554, 1992.